In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE ...

Oncologists never know which patients with dire prognoses will be among the rare, but real responders. The few who defy all ...

Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the ...

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...

Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep, with plans to start a ...

Dimensional Fund Advisors LP bought a new stake in shares of Mural Oncology plc (NASDAQ:MURA – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC.

Detailed price information for Aim Immunotech Inc (AIM-A) from The Globe and Mail including charting and trades.

In contrast, KEYNOTE-826 3 indicated slightly higher HRs for pembrolizumab when added to chemotherapy without bevacizumab. Given that bevacizumab has shown a proven overall survival benefit when added ...

The agency based its decision on results from the Phase III ALINA trial in which Alecensa improved disease-free survival in ALK-positive NSCLC patients.

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Nucana (NCNA – Research Report), ...